Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer

Cancer

Volumn 119, Issue 8, 2013, Pages 1593-1601

  Boland, Genevieve M ^a   Chang, George J ^a   Haynes, Alex B ^a   Chiang, Yi Ju ^a   Chagpar, Ryaz ^b   Xing, Yan ^a   Hu, Chung Yuan ^a   Feig, Barry W ^a   You, Y Nancy ^a   Cormier, Janice N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

colonic neoplasms; health care disparities; multivariate analysis; outcome assessment; standards; survival analysis

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COLON ADENOCARCINOMA; COLON CANCER; DATA BASE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; NATIONAL COMPREHENSIVE CANCER NETWORK GUIDELINE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COLONIC NEOPLASMS; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; QUALITY CONTROL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 84876056447     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27935     Document Type: Article

References (40)

1. National Comprehensive Cancer Center (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Fort Washington, PA: NCCN; 2012. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. [Accessed December 4, 2012.]
2. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol. 1999; 17: 1356-1363.
3. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27: 3109-3116.
4. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol. 1989; 7: 1447-1456.
5. Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol. 1995; 13: 2936-2943.
6. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999; 17: 3553-3559.
7. Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011; 29: 3768-3774.
8. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350: 2343-2351.
9. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005; 23: 8671-8678.
10. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007; 25: 2198-2204.
11. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007; 25: 3456-3461.
12. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005; 352: 2696-2704.
13. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009; 27: 3117-3125.
14. Ychou M, Raoul JL, Douillard JY, et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol. 2009; 20: 674-680.
15. Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB,. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002; 20: 3999-4005.
16. Chagpar R, Xing Y, Chiang YJ, et al. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol. 2012; 30: 972-979.
17. Bilimoria KY, Stewart AK, Winchester DP, Ko CY,. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008; 15: 683-690.
18. Steele GD Jr, Winchester DP, Menck HR,. The National Cancer Data Base. A mechanism for assessment of patient care. Cancer. 1994; 73: 499-504.
19. Winchester DP, Stewart AK, Phillips JL, Ward EE,. The National Cancer Data Base: past, present, and future. Ann Surg Oncol. 2010; 17: 4-7.
20. Dickman PW, Sloggett A, Hills M, Hakulinen T,. Regression models for relative survival. Stat Med. 2004; 23: 51-64.
21. Shah BR, Laupacis A, Hux JE, Austin PC,. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol. 2005; 58: 550-559.
22. Suh HS, Hay JW, Johnson KA, Doctor JN,. Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias. Pharmacoepidemiol Drug Saf. 2012; 21: 470-484.
23. Quasar Collaborative G, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007; 370: 2020-2029.
24. Wilkinson NW, Yothers G, Lopa S, Costantino JP, Petrelli NJ, Wolmark N,. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol. 2010; 17: 959-966.
25. Wolmark N, Bryant J, Smith R, et al. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J the Natl Cancer Inst. 1998; 90: 1810-1816.
26. Benson AB 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004; 22: 3408-3419.
27. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L,. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004; 22: 3395-3407.
28. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004; 22: 1797-1806.
29. Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009; 27: 872-877.
30. Rhoads KF, Cullen J, Ngo JV, Wren SM,. Racial and ethnic differences in lymph node examination after colon cancer resection do not completely explain disparities in mortality. Cancer. 2012; 118: 469-477.
31. Richards CA, Kerker BD, Thorpe L, et al. Increased screening colonoscopy rates and reduced racial disparities in the New York Citywide campaign: an urban model. Am J Gastroenterol. 2011; 106: 1880-1886.
32. Laiyemo AO, Doubeni C, Pinsky PF, et al. Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst. 2010; 102: 538-546.
33. Berry J, Caplan L, Davis S, et al. A black-white comparison of the quality of stage-specific colon cancer treatment. Cancer. 2010; 116: 713-722.
34. Etzioni DA, El-Khoueiry AB, Beart RW Jr,. Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review. Cancer. 2008; 113: 3279-3289.
35. O'Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011; 29: 3381-3388.
36. National Cancer Institute; Surveillance, Epidemiology, and End Results (SEEER) Program. SEER Cancer Statistics Review 1975-2008. Bethesda, MD: National Cancer Institute; 2009.
37. Robbins AS, Siegel RL, Jemal A,. Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008. J Clin Oncol. 2012; 30: 401-405.
38. Robbins AS, Pavluck AL, Fedewa SA, Chen AY, Ward EM,. Insurance status, comorbidity level, and survival among colorectal cancer patients age 18 to 64 years in the National Cancer Data Base from 2003 to 2005. J Clin Oncol. 2009; 27: 3627-3633.
39. Kelz RR, Gimotty PA, Polsky D, Norman S, Fraker D, DeMichele A,. Morbidity and mortality of colorectal carcinoma surgery differs by insurance status. Cancer. 2004; 101: 2187-2194.
40. Koroukian SM, Bakaki PM, Raghavan D,. Survival disparities by Medicaid status: an analysis of 8 cancers. Cancer. 2012; 118: 4271-4279.